A team at Biohub reported that co‑injecting a three‑amino‑acid cocktail with lipid nanoparticles markedly increased in vivo mRNA delivery and CRISPR editing efficiency in preclinical models, attributing gains to improved cellular receptivity under physiologic metabolic conditions. The paper in Science Translational Medicine suggests a metabolic approach to enhance existing LNP platforms without extensive nanoparticle redesign. Complementing that work, researchers developed an in vivo assay to directly quantify nanoparticle cargo release efficiency in mice, offering a standardized tool to evaluate and compare delivery vehicles. Together the studies deliver actionable methods to improve therapeutic nucleic acid delivery and to benchmark future delivery innovations.